tradingkey.logo

COSCIENS Biopharma Inc

CSCI
2.720USD
0.0000.00%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
8.64MMarktkapitalisierung
VerlustKGV TTM

COSCIENS Biopharma Inc

2.720
0.0000.00%

mehr Informationen über COSCIENS Biopharma Inc Unternehmen

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

COSCIENS Biopharma Inc Informationen

BörsenkürzelCSCI
Name des UnternehmensCOSCIENS Biopharma Inc
IPO-datumDec 19, 1995
CEOMs. Anna Biehn
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeDec 19
AddresseC/O Norton Rose Fulbright Canada Llp
StadtTORONTO
BörseThe Toronto Stock Exchange
LandCanada
PostleitzahlM5K 1E7
Telefon18439003201
Websitehttps://www.cosciensbio.com/
BörsenkürzelCSCI
IPO-datumDec 19, 1995
CEOMs. Anna Biehn

Führungskräfte von COSCIENS Biopharma Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Ulrich Kosciessa
Dr. Ulrich Kosciessa
Director
Director
1.85K
--
Mr. Robert A. Seager
Mr. Robert A. Seager
Director
Director
--
--
Ms. Nicola Ammer
Ms. Nicola Ammer
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
--
--
Dr. Matthias Gerlach
Dr. Matthias Gerlach
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
--
--
Mr. Giuliano La Fratta
Mr. Giuliano La Fratta
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Mr. Michel Regnier
Mr. Michel Regnier
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Ronald W. (Ronnie) Miller
Mr. Ronald W. (Ronnie) Miller
Director
Director
--
--
Mr. Peter H. Puccetti
Mr. Peter H. Puccetti
Chairman of the Board, Interim Chief Executive Officer
Chairman of the Board, Interim Chief Executive Officer
--
--
Mr. David Spear
Mr. David Spear
Director
Director
--
--
Mr. Anthony J. Giovinazzo
Mr. Anthony J. Giovinazzo
Director
Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Ulrich Kosciessa
Dr. Ulrich Kosciessa
Director
Director
1.85K
--
Mr. Robert A. Seager
Mr. Robert A. Seager
Director
Director
--
--
Ms. Nicola Ammer
Ms. Nicola Ammer
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
--
--
Dr. Matthias Gerlach
Dr. Matthias Gerlach
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
--
--
Mr. Giuliano La Fratta
Mr. Giuliano La Fratta
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Mr. Michel Regnier
Mr. Michel Regnier
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--

Umsatzaufteilung

Währung: USDAktualisiert: Sun, Apr 6
Währung: USDAktualisiert: Sun, Apr 6
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
Switzerland
4.32M
95.98%
Ireland
122.00K
2.71%
Other
48.00K
1.07%
Denmark
11.00K
0.24%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Thu, Jan 29
Aktualisiert: Thu, Jan 29
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Goodwood Inc.
8.08%
Gagnon (Gilles R)
1.32%
Li (William W. M.D.)
0.08%
Kosciessa (Ulrich)
0.06%
Prefontaine (Stacy)
0.02%
Andere
90.44%
Aktionäre
Aktionäre
Anteil
Goodwood Inc.
8.08%
Gagnon (Gilles R)
1.32%
Li (William W. M.D.)
0.08%
Kosciessa (Ulrich)
0.06%
Prefontaine (Stacy)
0.02%
Andere
90.44%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
8.08%
Individual Investor
1.48%
Andere
90.44%

Institutionelle Beteiligung

Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
31
257.31K
8.08%
-38.39K
2025Q3
32
283.56K
8.74%
-15.54K
2025Q2
37
331.27K
10.53%
-6.89K
2025Q1
40
333.44K
10.61%
+29.17K
2024Q4
39
327.35K
8.67%
+13.77K
2024Q3
37
287.99K
7.73%
+16.16K
2024Q2
43
256.95K
8.09%
+189.65K
2024Q1
39
61.15K
4.98%
+40.02K
2023Q4
42
13.03K
1.07%
-9.47K
2023Q3
49
18.14K
1.49%
-6.74K
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Goodwood Inc.
257.26K
8.08%
--
--
Jun 03, 2025
Gagnon (Gilles R)
41.96K
1.32%
--
--
Mar 26, 2025
Li (William W. M.D.)
2.40K
0.08%
--
--
Mar 26, 2025
Kosciessa (Ulrich)
1.85K
0.06%
--
--
Jun 03, 2025
Prefontaine (Stacy)
767.00
0.02%
+767.00
--
Jun 03, 2024
Osaic Holdings, Inc.
50.00
0%
--
--
Sep 30, 2025
Planning Capital Management Corp
2.00
0%
--
--
Sep 30, 2024
Mehr Anzeigen

Verbundene ETFs

Name
Anteil
Keine Daten

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
May 01, 2024
Merger
4→1
May 01, 2024
Merger
4→1
May 01, 2024
Merger
4→1
May 01, 2024
Merger
4→1
Jul 19, 2022
Merger
25→1
Jul 19, 2022
Merger
25→1
Datum
Ex-Dividendentag
Art
Verhältnis
May 01, 2024
Merger
4→1
May 01, 2024
Merger
4→1
May 01, 2024
Merger
4→1
May 01, 2024
Merger
4→1
Jul 19, 2022
Merger
25→1
Jul 19, 2022
Merger
25→1
Jul 19, 2022
Merger
25→1
Jul 19, 2022
Merger
25→1
KeyAI